---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-007071"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:38:47.289330+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Phio Pharma reports 2025 net loss $8.7M; PH-762 Phase 1b dose escalation complete with favorable data

## Summary
- Net loss of $8.7M ($1.45 EPS) for 2025 vs $7.2M ($9.08 EPS) in 2024; R&D expenses up 27%.
- Cash at Dec 31, 2025: $21.0M vs $5.4M year ago; net proceeds from 2025 financings of $20.6M extend runway into H1 2027.
- PH-762 Phase 1b dose escalation trial fully enrolled (22 patients); final cohort shows favorable safety, tolerability and pathology.
- FDA submission seeking guidance on next steps for PH-762 targeted for Q2 2026; patent portfolio includes 54 issued patents.
- Phio entered drug substance development agreement with US manufacturer and toxicology study agreement with US lab in 2025.

## SEC filing metadata
- accession: 0001437749-26-007071
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000143774926007071/0001437749-26-007071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000143774926007071/phio20251215_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-007071
- JSON: https://secwatch.observer/filing/0001437749-26-007071.json
- Plain text: https://secwatch.observer/filing/0001437749-26-007071.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.